+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature

Medical Oncology 25(3): 323-330

To identify potential tolerability issues for a novel selective p38 Mitogen-activated Protein Kinases (p38MAPK) inhibitor, we performed a systematic review of published studies and abstracts reporting safety outcomes for indirect inhibitors of p38MAPK. A systematic review was performed to identify articles and meeting abstracts published between January 1, 1990 and March 31, 2005 that reported safety outcomes in cancer patients. Study, patient, and treatment level data were summarized using descriptive statistics without meta-analyses. Of 2,408 studies identified in the search, only 174 met eligibility criteria. Most studies (90%) involved thalidomide (or analog); only 12 (8%) studied sorafenib and 5 studied anti-tumor necrosis factor antibodies. In 165 treatment arms, 32% involved thalidomide (or analog) monotherapy and 2.4% involved sorafenib. The tolerability profiles of the two agents differed markedly. The most common Grade 3/4 adverse events experienced on thalidomide monotherapy were venous thrombosis (3.1% of patients), weakness/asthenia/fatigue (3.0%), neutropenia (2.7%), peripheral neuropathy/tingling/numbness (2.4%), somnolence/drowsiness/lethargy (2.4%), constipation (2.1%), and infection (2.0%). In contrast, the most common Grade 3/4 toxicities with sorafenib were diarrhea (4.8%), weakness/asthenia/fatigue (4.0%), hand-foot syndrome (3.2%), and leukopenia (2.4%). For both types of inhibitors, abnormal liver function tests were reported in about 3% of patients. The present review summarizes clinical safety information of anti-cancer drugs with indirect or nonspecific p38MAPK inhibitory activity. Based on our analysis, a novel p38MAPK inhibitor should be monitored for similar neurological, gastrointestinal, and cardiovascular symptoms in Phase I clinical trials.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056093117

Download citation: RISBibTeXText

PMID: 18204822

DOI: 10.1007/s12032-008-9039-1

Related references

Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. Current Drug Safety 4(2): 143-154, 2009

Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature. Current Drug Safety 4(2): 143-154, 2009

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Therapy 9(4): 1491-1500, 2018

The direct and indirect costs associated with endometriosis: a systematic literature review. Human Reproduction 31(4): 712-722, 2016

Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature. Drug Safety 34(12): 1125-1149, 2012

Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. Journal of Antimicrobial ChemoTherapy 72(11): 2990-3007, 2017

Second-Line Treatment of Metastatic Colorectal Cancer (mCRC): A Systematic Literature Review (SLR) and Feasibility Assessment of Conducting Indirect Treatment Comparison (ITC) Analysis. Value in Health 16(7): A395-A396, 2013

Direct and indirect measurement of physical activity in older adults: a systematic review of the literature. International Journal of Behavioral Nutrition and Physical Activity 9: 148, 2013

Sentinel lymph node biopsy to direct treatment in gastric cancer. A systematic review of the literature. European Journal of Surgical Oncology 37(8): 655-661, 2011

The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. American Journal of Obstetrics and Gynecology 213(2): 141-160, 2015

Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thrombosis Research 169: 123-127, 2018

What are the differences between a literature search, a literature review, a systematic review and a meta-analysis? And why is a systematic review considered to be so good?. Irish Medical Journal 106(2 Suppl.): 8-10, 2013

Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. Expert Opinion on Investigational Drugs 25(7): 781-796, 2017

Pdb12 - Cardiovascular Safety Of Empagliflozin Versus Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists: Systematic Literature Review And Indirect Comparisons. Value in Health 21: S120-S121, 2018

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Lung Cancer 19(3): E335-E348, 2018